Bactiguard Holding AB
STO:BACTI B
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
33.4
93.9
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Bactiguard Holding AB
Bactiguard Holding AB
Cost of Revenue
Bactiguard Holding AB
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bactiguard Holding AB
STO:BACTI B
|
Cost of Revenue
-kr161.9m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
O
|
OssDsign AB
STO:OSSD
|
Cost of Revenue
-kr28.5m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Xvivo Perfusion AB
STO:XVIVO
|
Cost of Revenue
-kr192.1m
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
-26%
|
|
|
D
|
Doxa AB
STO:DOXA
|
Cost of Revenue
-kr5.1m
|
CAGR 3-Years
23%
|
CAGR 5-Years
25%
|
CAGR 10-Years
12%
|
|
|
V
|
Vimian Group AB
STO:VIMIAN
|
Cost of Revenue
-€187.2m
|
CAGR 3-Years
-60%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
S2Medical AB (publ)
STO:S2M
|
Cost of Revenue
-kr1.1m
|
CAGR 3-Years
39%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bactiguard Holding AB
Glance View
Bactiguard Holding AB is a medical device company, which engages in the development and supply of infection protection solutions. The company is headquartered in Stockholm, Stockholm and currently employs 188 full-time employees. The company went IPO on 2014-06-19. Its technology is based on the Bactiguard Infection Protection (BIP), a thin coating permanently bound to the surface of medical devices. The company consists of the noble metals: gold, palladium and silver, which reduces the adhesion of bacteria to the coated surfaces. Its product portfolio includes: BIP Foley Catherer, made from medical grade latex, and BIP Foley Catheter - Silicone, used for drainage and irrigation of the bladder; BIP Endotracheal Tube, for general anesthesia, intensive care, and emergency medicine for airway management and mechanical ventilation; and BIP Central Venous Catherer, made of polyurethane and used to administer drugs and intravenous solutions, monitor pressure and blood sampling. The firm is also present in Portugal, via a distribution agreement with Socime Medical Ltd, and Zambia.
See Also
What is Bactiguard Holding AB's Cost of Revenue?
Cost of Revenue
-161.9m
SEK
Based on the financial report for Dec 31, 2023, Bactiguard Holding AB's Cost of Revenue amounts to -161.9m SEK.
What is Bactiguard Holding AB's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-15%
Over the last year, the Cost of Revenue growth was -28%. The average annual Cost of Revenue growth rates for Bactiguard Holding AB have been -24% over the past three years , -15% over the past five years .
You don't have any saved screeners yet
